MOUNT PLEASANT, S.C., Oct. 3 /PRNewswire-FirstCall/ -- Maxxon, Inc. announced today that the company has received its first shipment of sterile product: 5,000 units of the ReVac Safety Syringe. ReVac is the flagship product of Maxxon, Inc., and receiving the first batch of sterile product represents a significant milestone for the company as it allows for controlled trial use and submission to the Food and Drug Administration (FDA) for 510k approval.
Maxxon Inc. President Ron Wheet announced, “We couldn’t be more optimistic about our company’s future now that we have received the first batch of sterile product. ReVac has gone through extensive years of R&D and we’ve made countless improvements to every aspect of the product in order to produce the best possible technology for our market. The entire company believes that the final version of ReVac exceeds all industry standards for safety, efficacy and cost-effectiveness. We expect that the market will show an overwhelmingly positive response to our patented technology, and at our price point, I foresee that we will become a major player in our field very quickly.”
About Maxxon Inc:
Maxxon operates in the safety-engineered medical devices (SEMDs) arena. Its products include the ReVac Safety Syringe, Auto-Retractable Safety Scalpel with Permanent Lock and the Auto-Retractable Safety IV Catheter. The world market for SEMDs was projected to exceed $1.6 billion last year and is forecast to maintain a 20% annual growth rate in the near term.
In the United States, the safety syringe market is expected to generate approximately $693 million in revenues in 2006, representing 66% of the total needles and syringes market. The Theta Report estimated the number of needles and syringes sold in the U.S. and international market combined should exceed 20 billion units in 2006.
For more information on Maxxon, please go to http://www.maxxoninc.com.
Safe Harbor
Forward-looking statements made in this release are made pursuant to the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made by Maxxon Inc. are not a guarantee of future performance. This news release includes forward-looking statements, including with respect to the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties and events that may be beyond the control of Maxxon Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain and successfully complete projects, and changes in products and competition.
For investor relations information, contact: Gabe Sandler Sandler Communications, Inc. Phone: 866-772-0118 Email: info@sandlercommunications.com
Maxxon, Inc.
CONTACT: Gabe Sandler of Sandler Communications, Inc., 1-866-772-0118,info@sandlercommunications.com
Web site: http://www.maxxoninc.com/